Daniel Wendling1,2, Clément Prati3,4, Mickael Chouk3, Frank Verhoeven3,4. 1. Department of Rheumatology, CHRU de Besançon (University Teaching Hospital), Boulevard Fleming, 25030, Besançon, France. dwendling@chu-besancon.fr. 2. EA 4266, EPILAB, Université de Franche-Comté, Rue Ambroise Paré, 25030, Besançon, France. dwendling@chu-besancon.fr. 3. Department of Rheumatology, CHRU de Besançon (University Teaching Hospital), Boulevard Fleming, 25030, Besançon, France. 4. EA 4266, PEPITE, Université de Franche-Comté,, Rue Ambroise Paré, 25030, Besançon, France.
Abstract
PURPOSE OF THE REVIEW: Reactive arthritis is synovitis related to an infection away from the joint. The evolution is variable, frequently self-limited, but with the possible evolution to a prolonged form, generating functional incapacity and sequelae. RECENT FINDINGS: New microbiological families have been incriminated and pathophysiological links have been clarified, highlighting the role of the mucous membranes (gut in particular), specific cell populations, and the production of pro-inflammatory cytokines. First-line pharmacological treatment is based on NSAIDs. In case of failure, synthetic and more recently biological DMARDs are indicated. Only open data are available for biological DMARDs but suggest good efficacy and safety. Reactive arthritis has not disappeared. The diagnosis must be mentioned by the clinic and history to allow the rapid introduction of an appropriate treatment.
PURPOSE OF THE REVIEW: Reactive arthritis is synovitis related to an infection away from the joint. The evolution is variable, frequently self-limited, but with the possible evolution to a prolonged form, generating functional incapacity and sequelae. RECENT FINDINGS: New microbiological families have been incriminated and pathophysiological links have been clarified, highlighting the role of the mucous membranes (gut in particular), specific cell populations, and the production of pro-inflammatory cytokines. First-line pharmacological treatment is based on NSAIDs. In case of failure, synthetic and more recently biological DMARDs are indicated. Only open data are available for biological DMARDs but suggest good efficacy and safety. Reactive arthritis has not disappeared. The diagnosis must be mentioned by the clinic and history to allow the rapid introduction of an appropriate treatment.
Authors: Mohammad Vahedian Ardakani; Sara Parviz; Ehsan Ghadimi; Zahra Zamani; Mohammadreza Salehi; Mohammad Ayati Firoozabadi; S M Javad Mortazavi Journal: J Orthop Surg Res Date: 2022-06-06 Impact factor: 2.677